Top

Published in:

01-08-2012 | Research Article

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer

Authors: Ramon Salazar, Matilde Navarro, Ferran Losa, Vicente Alonso, Manel Gallén, Fernando Rivera, Manuel Benavides, Pilar Escudero, Encarnación González, Bartomeu Massutí, Auxiliadora Gómez, Margarita Majem, Enrique Aranda

Published in: Clinical and Translational Oncology | Issue 8/2012

Abstract

Introduction

A prospective phase II study was conducted to assess the clinical activity and tolerability of oxaliplatin, capecitabine, and radiotherapy (RT) for neoadjuvant therapy of stages II–III rectal cancer.

Materials and methods

Patients with histologically confirmed stages II–III (T3–T4 and/or N+) resectable rectal adenocarcinoma were eligible. Capecitabine was administered at 825 mg/m² twice daily for 5 days/week and oxaliplatin at 50 mg/m² on day 1 weekly for 5 weeks starting the first day of RT (before RT). RT consisted of a total dose of 45 Gy delivered in 25 fractions of 1.8 Gy, 5 days per week, for 5 weeks.

Results

A total of 46 patients were included (35 male, 10 female, median age 62 years). TNM Stage was T3 in 43 patients and T4 in 2. Twenty-eight patients had suspected nodal involvement. The intended chemoradiation treatment was completed in 94 % patients. Grade 3/4 toxicity included lymphocytopenia (6 patients), diarrhea (4 patients), emesis (2 patients), asthenia (3 patients), anorexia (1 patient), and hepatic toxicity (1 patient). Grade 1 neurotoxicity occurred in 18 patients, Grade 2 neurotoxicity in 3, and Grade 1 palmoplantar erythrodysesthesia in 2. Forty-two patients underwent surgery (complete resection 95 %, sphincter-saving operation 55 %). The overall pathologic response rate was 83 %, with a pathologic complete response (pCR) rate of 11.9 % (95 % CI 4.0–25.6).

Conclusions

The pCR rate observed with oxaliplatin plus capecitabine and RT did not reach the pre-specified criteria of efficacy in this trial, which is in line with recent results of randomized phase III trials.

Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123PubMedCrossRef

Gérard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef

Pasetto LM, Pucciarelli S, Agostini M, Rossi E, Monfardini S (2004) Neoadjuvant treatment for locally advanced rectal carcinoma. Crit Rev Oncol Hematol 52:61–71PubMedCrossRef

Smalley SR, Benedetti JK, Williamson SK et al (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24:3542–3547PubMedCrossRef

Yerushalmi R, Idelevich E, Dror Y et al (2006) Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol 93:529–533PubMedCrossRef

De Paoli A, Chiara S, Luppi G et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17:246–251PubMedCrossRef

Desai SP, El-Rayes BF, Ben-Josef E et al (2007) A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol 30:340–345PubMedCrossRef

Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091PubMedCrossRef

10.

Díaz-Rubio E, Tabernero J, Gómez-España A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25:4224–4230PubMedCrossRef

11.

Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000–1005PubMedCrossRef

12.

Willeke F, Horisberger K, Kraus-Tiefenbacher U et al (2007) A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96:912–917PubMedCrossRef

13.

Corvò R, Pastrone I, Scolaro T et al (2003) Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives. Tumori 89:361–367PubMed

14.

Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC (2006) A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOC-RT) in patients with locally advanced rectal cancer. Ann Oncol 17:50–56PubMedCrossRef

15.

Koeberle D, Burkhard R, von Moos R et al (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98:1204–1209PubMedCrossRef

16.

Navarro M, Dotor E, Rivera F et al (2006) A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66:201–205PubMedCrossRef

17.

Aristu JJ, Arbea L, Rodriguez J et al (2008) Phase-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 71:748–755PubMedCrossRef

18.

Hospers GA, Punt CJ, Tesslaar ME et al (2007) Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I–II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 14:2773–2779PubMedCrossRef

19.

Fakih M, Bullarddunn K, Yang GY (2008) Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 72:650–657PubMedCrossRef

20.

Heudel P, Romestaing P, Barbet N et al (2008) Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 Phase I Trial. Clin Oncol 20:369–374CrossRef

21.

Klautke G, Fietkau R (2007) Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. Int J Colorectal Dis 22:457–465PubMedCrossRef

22.

Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0, 1998. http://ctep.cancer.gov/reporting/ctc.html

23.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef

24.

Weiser MR (2011) Rectal cancer trials: no movement. J Clin Oncol 29:2746–2748PubMedCrossRef

25.

Hoffe SE, Shridhar R, Biagioli MC (2010) Radiation therapy for rectal cancer: current status and future directions. Cancer Control 17:25–34PubMed

26.

Machiels JP, Duck L, Honhon B et al (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16:1898–1905PubMedCrossRef

27.

Chau I, Brown G, Cunningham D et al (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668–674PubMedCrossRef

28.

Rödel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110–117PubMedCrossRef

29.

Gérard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III Trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644PubMedCrossRef

30.

Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with and without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780PubMedCrossRef

31.

Roh MS, Yothers GA, O’Connell MJ et al (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29(suppl; abstr 3503)

32.

Roedel C, Becker H, Fietkau R et al (2011) Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 29(suppl; abstr LBA3505)

Title: Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer
Authors: Ramon Salazar
Matilde Navarro
Ferran Losa
Vicente Alonso
Manel Gallén
Fernando Rivera
Manuel Benavides
Pilar Escudero
Encarnación González
Bartomeu Massutí
Auxiliadora Gómez
Margarita Majem
Enrique Aranda
Publication date: 01-08-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 8/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0846-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2012

Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome

Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells

Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management. A guideline of the TTD group

Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases. A retrospective analysis of a single center

Keynote webinar | Spotlight on antibody–drug conjugates in cancer